Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether topical (intranasal) steroids changes presence/persistence of OME (short‐term); assumed ICC = 0.5 compared with no treatment (very low certainty).
1 finding from 1 review
RR 0.72 [0.57, 0.91]
Studies not reported
Very low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Death or dependence · acute ischaemic stroke
Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).
1 finding from 1 review
Death from any cause during · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).
1 finding from 1 review
Pulmonary embolism · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).
1 finding from 1 review
Recurrent ischaemic or unknown stroke during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).
1 finding from 1 review
Symptomatic intracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Major extracranial haemorrhage during treatment period · acute ischaemic stroke
It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).
1 finding from 1 review
Complete recovery from stroke (post hoc) · acute ischaemic stroke
Antiplatelet drug probably leads to higher complete recovery from stroke (post hoc) compared with control (moderate certainty).
1 finding from 1 review
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant probably leads to lower global evaluation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: all · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant leads to higher adverse effects: all compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: drowsiness, hypersomnia, lethargy, excessive… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: dry mouth · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: dry mouth compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: gastrointestinal compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: dizziness, lightheadedness · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant leads to higher adverse effects: dizziness, lightheadedness compared with placebo (high certainty).
1 finding from 1 review
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic‐decongestant showed no clear difference in global evaluation: after 3 days of treatment (included children 2 to… compared with placebo (low certainty).
2 findings from 1 review
Global evaluation: after 5 days of treatment (included children 2 to 12 years old only) · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic‐decongestant showed no clear difference in global evaluation: after 5 days of treatment (included children 2 to… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: all · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant showed no clear difference in adverse effects: all compared with placebo (moderate certainty).
1 finding from 1 review